Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus SPRX 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus SPRX 3.
IMPOYZ vs SPRX-3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Selective sigma-2 receptor ligand; induces mitochondrial dysfunction and endoplasmic reticulum stress leading to apoptosis in cancer cells. Also modulates autophagy.
100 mg orally twice daily
Not established; investigational drug. No approved standard adult dose available.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 12 ± 3 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily renal (70% unchanged, 15% as glucuronide conjugate); biliary/fecal (10%); other (5%).
Category C
Category C
Unknown
Unknown